{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mdluli T"],"funding":["NIAID NIH HHS"],"pagination":["114344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(6)"],"pubmed_abstract":["A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post"],"journal":["Cell reports"],"pubmed_title":["Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption."],"pmcid":["PMC11298786"],"funding_grant_id":["UM1 AI126603"],"pubmed_authors":["Kroon E","Pinyakorn S","Rolland M","Phanupak N","Vasan S","Tran U","Schuitemaker H","Hsu DC","Trautmann L","Dussupt V","Stieh DJ","Slike BM","de Souza M","Ake JA","Colby DJ","Ananworanich J","Pau MG","Shubin Z","Mdluli T","Mendez-Rivera L","Sacdalan C","Curtis DJ","Li Y","Tomaka FL","Robb ML","Krebs SJ","Paquin-Proulx D"],"additional_accession":[]},"is_claimable":false,"name":"Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.","description":"A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-01T15:24:59.777Z","creation":"2025-02-19T04:40:53.562Z"},"accession":"S-EPMC11298786","cross_references":{"pubmed":["38850529"],"doi":["10.1016/j.celrep.2024.114344"]}}